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Background: The high variability in clinical manifestations of Fabry disease can lead 
to delays between symptom onset and correct diagnosis, and between correct 
diagnosis and initiation of enzyme replacement therapy. We investigated whether 
these delays have improved in recent years.  
Methods: Data were analyzed from the Fabry Outcome Survey (FOS; Shire; 
extracted August 2013) for “index patients”, defined as the first patient diagnosed 
with Fabry disease from a family with several or no additional members registered in 
FOS.  
Results: Periods analyzed: 2001–2006 versus 2007–2013, in patients overall and 
from Europe versus the rest of the world (ROW). Overall, 598 patients were 
diagnosed within the study periods. Median age (95% CI) at symptom onset in 
2001–2006 and 2007–2013 was 7.0 (5.0–11.0) and 9.0 (6.0–11.0) in children, and 
21.0 (15.0–28.0) and 31.0 (26.0–35.0) in adults, respectively. Overall, the delay in 
diagnosis did not improve, despite showing a trend towards earlier diagnosis in 
adults (median 14.0 [95% CI 9.0–20.0] vs. 10.5 [8.0–13.0] years) and children (5.0 
[1.0–9.0] vs. 4.0 [0.0–8.0] years). In contrast, the delay in treatment onset 
significantly decreased from 2001–2006 to 2007–2013 in children (4.3 [2.0–7.0] vs. 
1.0 [0.8–1.4] year; p < 0.001) and adults (2.1 [1.3–3.2] vs. 0.9 [0.8–1.1] years; p < 
0.001). Geographically, the delay in treatment onset significantly decreased in the 
ROW among children (5.3 [4.2–8.0] vs. 1.0 [0.8–1.4] year; p < 0.001) and adults (5.4 
[4.8–6.0] vs. 1.1 [0.9–1.1] year; p < 0.001), but it did not change in Europe.  
Conclusion: We found that the delay in diagnosis has not improved substantially 
whereas the delay in treatment onset has improved in recent years.  
 






What is already known about this topic? 
The heterogeneous nature and severity of Fabry disease symptoms, plus wide 
variations in the age at which they manifest, can hinder a correct diagnosis of this 
disease, delaying treatment initiation. Enzyme replacement therapy is considered 
most beneficial when started early in the disease course; therefore, it is essential 
that awareness and knowledge of Fabry disease be spread amongst the medical 
community to shorten the time to diagnosis.  
 
What does this article add? 
We investigate whether knowledge regarding diagnosis and treatment of Fabry 
disease has improved in recent years. By analyzing data from index patients 
included in the Fabry Outcome Survey, we found that the delay in treatment onset 
has significantly improved, although the delay in diagnosis has not. Our geographical 
analysis shows a significant decrease in treatment delay for patients outside of 
Europe compared with those within, and we also show how numbers diagnosed by 
















Fabry disease is an X-linked lysosomal storage disorder caused by a functional 
deficiency of alpha-galactosidase A. Deficiency of this enzyme results in progressive 
accumulation of glycosphingolipids, particularly globotriaosylceramide (Gb3), in many 
different cell types throughout the body [1]. Clinical manifestations of classical Fabry 
disease typically begin in adolescence, including acroparesthesia and abdominal 
pain [2], and progress over the disease course, resulting in premature death from 
renal, cardiovascular, or cerebrovascular complications, often around the fifth 
decade of life in men [3] and seventh in women [4]. Until recently, Fabry disease in 
women was thought to be largely asymptomatic [1], but closer observations have 
revealed that women may experience the same signs and symptoms as men, 
although typically with a higher degree of variability and occurring later in life [5, 6]. 
Enzyme replacement therapy (ERT) has been shown to stabilize and improve 
many of the signs and symptoms of Fabry disease [7-12]. Starting treatment early in 
the disease course may halt the progression towards irreversible organ damage and 
the subsequent development of associated life-threatening complications. 
Unfortunately, the diagnosis of Fabry disease is confounded by high variability in 
terms of organ system involvement, age at onset, and severity of Fabry disease 
clinical features, often resulting in misdiagnosis or delayed diagnosis [13]. Patients 
may seek help from multiple medical specialists before a correct diagnosis is made, 
resulting in delayed treatment initiation.  
A study of FOS data soon after ERT for Fabry disease became available in 
2001, identified mean delays from symptom onset to correct Fabry disease diagnosis 
of 13.7 years in males and 16.3 years in females [6]. Subsequent research showed 
only a slight improvement in mean delay (12.2 years in males and 12.4 years in 






females) [14], indicating that provision of treatment early in the course of Fabry 
disease remained unlikely for many patients.  
Since the publication of earlier works analyzing the delay in Fabry disease 
diagnosis, several active educational projects have been conducted to spread the 
knowledge about this condition and to make the different specialists who could 
potentially encounter Fabry disease cases more familiar with it. Whether patients 
with Fabry disease are now being diagnosed sooner and started on treatment earlier 
in the disease course is unknown.  
The objective of this study was to evaluate whether delays in Fabry disease 
diagnosis and treatment have improved in recent years. 
 
Materials and methods 
Patients and study design 
Patient data were extracted from the Fabry Outcome Survey (FOS), an international 
registry initiated in 2001 (sponsor: Shire) for the collection of long-term data to help 
increase the understanding of the natural history of Fabry disease. The data 
extraction date for this study was August 2013. Patients diagnosed with Fabry 
disease who are untreated or receiving treatment with agalsidase alfa are eligible for 
inclusion in FOS. The Ethics Committees/Institutional Review Boards of all 
participating centers have approved conduct of the FOS registry. All patients, or their 
caregivers or legal guardians in the case of children, provide written informed 
consent/assent before data can be entered into the FOS database, and the data are 
anonymized prior to analysis. 
The current study focuses on FOS index patients. “Index patient” was 
previously defined as a patient with Fabry disease who was not diagnosed as a 






result of having an affected family member [6]. This study includes the first patient 
with a diagnosis of Fabry disease from a family with several members or no 
additional members registered in FOS. Patients were excluded if they had a negative 
delay in diagnosis (i.e. if they were diagnosed before symptom onset). Children are 
defined as patients who were younger than 18 years of age at diagnosis. 
 
Data analysis 
Enzyme replacement therapy with agalsidase alfa became available in 2001. For the 
analyses herein, index patients registered in FOS from 2001 up to date (2013) were 
identified and divided into groups according to their year of diagnosis. The groupings 
of 2001–2006 and 2007–2013 were chosen so that a similar time period was 
covered by each group. To investigate whether the delay in Fabry disease diagnosis 
has decreased in recent years, the time between first symptoms and diagnosis in all 
patients (treated plus untreated) diagnosed between 2007 and 2013 was compared 
with that in patients diagnosed between 2001 and 2006. To investigate whether the 
delay between diagnosis and treatment onset has decreased since 2001, the time 
between Fabry disease diagnosis and treatment onset in patients diagnosed during 
2007–2013 was compared with that in treated patients diagnosed during 2001–2006.  
Delays in diagnosis and treatment onset were also evaluated for the 
geographical regions in which agalsidase alfa is approved for commercial use, 
designated herein as Europe and the rest of the world (ROW).   
The severity of disease manifestations reported for adult patients diagnosed 
during 2001–2006 and 2007–2013 was assessed using the FOS-Mainz Severity 
Score Index (FOS-MSSI) obtained at treatment onset. The type of specialist who first 
suspected Fabry disease was also analyzed in patients diagnosed before 2006 (thus 






including patients who were diagnosed before the FOS registry was initiated and 
who were subsequently entered into the database) and during 2007–2013.  
 
Statistical analyses 
Descriptive statistics were calculated and differences were assessed using Fisher’s 
exact tests for categorical variables and Wilcoxon rank sum tests for continuous 




At the time of data extraction, 598 patients had been diagnosed within the study 
periods (Figure 1) and are included herein. This study focuses on the delay in 
diagnosis and treatment onset; however, age at diagnosis, symptom onset, and ERT 
initiation is provided for reference in the Supporting Information Table S1.   
 
Delay in diagnosis 
A trend towards early diagnosis was noted for both children and adults, although 
none of the differences were statistically significant (Table 1). Moreover, many 
patients continue to experience delays in Fabry disease diagnosis of 30 years and 
more (Figure 2).  
Of a total of 598 index patients enrolled in FOS and included in our study, 267 
(44.6%) were from Europe and 331 (55.4%) were from the ROW. For children, no 
statistically significant differences were found in the delay in diagnosis during 2007–
2013 compared with 2001–2006 in either region (Table 2). Considering only adults, 






we identified a shorter delay in diagnosis during the more recent period only in 
Europe (p = 0.048; Table 2). 
 
Delay in treatment onset 
The delay between Fabry disease diagnosis and treatment onset was statistically 
significantly shorter in children diagnosed during 2007–2013 (median 1.0 [95% CI 
0.8–1.4] year) than during 2001–2006 (4.3 [95% CI 2.0–7.0] years; p < 0.001; Table 
1). This delay in treatment onset was also statistically significantly shorter in adults 
diagnosed during 2007–2013 (0.9 [95% CI 0.8–1.1] years) than during 2001–2006 
(2.1 [95% CI 1.3-3.2] years; p < 0.001; Table 1).  
 
Geographical analysis 
The delay between Fabry disease diagnosis and treatment onset was shorter for 
children and adults in Europe than in the ROW during 2001–2006, but was quite 
similar during 2007–2013. No statistically significant change was found for either 
children or adults in Europe diagnosed during 2007–2013 when compared with those 
diagnosed during 2001–2006 (Table 2). However, a statistically significant decrease 
in the delay between Fabry disease diagnosis and treatment onset was found for 
both children and adults in the ROW. For children, the median delay shows a 
decrease from 5.3 (95% CI 4.2–8.0) years in those diagnosed during 2001–2006 to 
1.0 (95% CI 0.8–1.4) years in those diagnosed during 2007–2013 (p < 0.001; Table 
2). For adults, the median delay decreased from 5.4 (95% CI 4.8–6.0) years in those 
diagnosed during 2001–2006 to 1.1 (95% CI 0.9–1.1) years in those diagnosed 
during 2007–2013 (p < 0.001; Table 2). 
 






Disease expression and diagnosis by medical specialists 
Overall, adult FOS MSSI scores at treatment initiation did not differ between patients 
from each period. The FOS-MSSI scores at treatment initiation were lower in adult 
females than adult males during both 2007–2013 (p = 0.003) and 2001–2006 (p = 
0.016; Table 3). 
The aggregate proportion of index patients diagnosed by geneticists, general 
practitioners, pediatricians, and internists significantly increased in recent years 
(18.9% before 2006 vs. 39.6% in 2007–2013; p < 0.001) compared with no change 
in the aggregate proportion diagnosed by cardiologists, nephrologists, and 
neurologists (41.1% before 2006 vs. 41.6% in 2007–2013; Table 4). 
 
Discussion 
Delay in diagnosis 
The current study shows that, overall, the delay in Fabry disease diagnosis has 
shown a non-significant trend towards improvement in recent years. It also shows 
that ERT now seems to be initiated sooner after diagnosis than when it first became 
available. We found a similar mean delay in Fabry disease diagnosis in adults in 
recent years to that of the 13.7 years for males and 16.3 years for females described 
by Mehta et al in 2004 [6], and also the 12.2 years for males and 12.4 years for 
females reported by Beck in 2006 [14]. Moreover, the Fabry Registry reported an 
even larger gap between median age at symptom onset and diagnosis of 14 years 
for males and 19 years for females [15]. In agreement with findings from Mehta et al 
[6], we also found that some patients still experienced delays in excess of 30 years 
before a correct diagnosis was made (Figure 1). The reduction in median delay in 
diagnosis of 9.5 years in adult males is very encouraging but still insufficient, and 






shows that further efforts to reduce the delay in Fabry disease diagnosis are needed 
to improve patient care. The prompt diagnosis of index patients is also likely to result 
in earlier diagnosis of affected relatives and could have a strong impact on the 
management of a significant number of patients. A median of five Fabry disease 
carriers are diagnosed from each index patient identified [16]; therefore, the 
“cumulative impact” of prompt diagnosis within a family is not negligible. 
Patients with cardiac and renal Fabry disease variants may present with later-
onset left ventricular hypertrophy [17] or end-stage renal disease [18] without 
previous classical manifestations. The prevalence of these Fabry disease variants 
may be greater than originally thought [17, 18], and may help explain the delay in 
diagnosis experienced by some patients. Unfortunately, on this occasion, we were 
not able to confirm the number of patients with cardiac and renal variants of Fabry 
disease due to mutation data being unavailable. A previous analysis of FOS data, 
however, found no evidence of late-onset cardiac or renal variants with milder 
disease [6], although the definitions used to identify these Fabry disease variants 
were not provided. 
 
Delay in treatment onset 
Whilst other studies have investigated the delay between symptom onset and 
diagnosis in Fabry disease with reference to timely treatment strategies [6, 14], the 
delay between diagnosis and treatment onset has not been well investigated. In this 
study, the significant reduction in the delay between diagnosis and ERT initiation that 
was observed after 2007 is of utmost importance. The most likely reason for why we 
still have an important delay in recognizing Fabry disease patients is that during the 
diagnosis process physicians of many different specialties are involved and their 






awareness of this rare disorder is still limited. Nevertheless, once new Fabry disease 
patients have been identified, treatment could possibly be started earlier due to their 
referral to centers of great experience and thus awareness that early treatment is an 
essential goal for improving or stabilizing Fabry disease symptoms [19, 20]. 
 
Geographical analysis 
The improvement in delay in diagnosis in recent years for adults in Europe, and 
particularly the significant improvement in treatment delay in the ROW, may reflect 
wider education of Fabry disease and its signs and symptoms and improved 
availability of agalsidase alfa ERT in the ROW. The regional differences found in this 
study are relevant and a specific analysis of educational programs undertaken in 
Europe versus those performed in the ROW could shed light on which programs 
would be best carried out moving forward, now that ERT is widely available. 
 
Disease expression and diagnosis by medical specialists 
This study shows that adult patients diagnosed after 2007 had a similar level of 
disease severity as those diagnosed in 2001–2006. Improvements in the recognition 
of late-onset variants and less severe forms of Fabry disease in females could be 
expected to result in more patients with milder disease being diagnosed. In the 
current analysis, breakdown by gender revealed that neither males nor females 
differed significantly in disease severity between the diagnosis periods.  
The aggregate proportion of patients diagnosed with Fabry disease by 
geneticists, general practitioners, pediatricians, and internists appears to be 
approaching that diagnosed by cardiologists, nephrologists, and neurologists, which 
may reflect increasing awareness of this multi-systemic disorder throughout the 






wider medical community. This may explain the earlier diagnosis identified in some 
regions of the world, such as Europe. Geneticists were the leading specialists in 
diagnosing index patients with Fabry disease during 2007–2013. While a proportion 
of these index patients would have been diagnosed by geneticists through family 
screening, it is also recognized that many are likely to have been referred by other 
specialists who suspected Fabry disease, thus geneticists would have confirmed the 
final diagnosis. 
This study was subject to several limitations. FOS is a registry for real-world 
data collection and was not specifically designed to collect data on all of the 
parameters reported in this retrospective study. Furthermore, there is the possibility 
that data in FOS are subject to ascertainment bias, whereby patients with less 
severe Fabry disease may not have been diagnosed and therefore were not 
included. Also, age at symptom onset may be subject to recall bias. Though the FOS 
registry contains one of the largest datasets on Fabry disease, the sample sizes in 
our analysis remain small, especially for children, which may have prevented a 
statistically significant improvement in the delay in diagnosis from being reached. 
However, small samples sizes are to be expected in the rare disease arena. 
Despite efforts to increase education and awareness of Fabry disease in 
recent years, early recognition is still a challenge and an unmet need. There is still 
the necessity for pediatricians and pediatric rheumatologists to recognize when pain 
is neuropathic and not due to bone or joint origins. We need to increase awareness 
that angiokeratomas and cornea verticillata, as observed in routine controls, are 
frequent and early signs in Fabry disease. Earlier diagnosis may also be helped by 
ear, nose and throat specialists including Fabry disease among the differential 
diagnoses of sudden hearing loss. Since access to online health information has 






rapidly increased in recent years, websites dedicated to raising awareness of Fabry 
disease signs and symptoms in the general population could be an important tool. All 
of these factors will help increase the likelihood of Fabry disease being suspected 




Our analysis shows that the delay in diagnosis has decreased, but not significantly, 
while the delay in treatment onset has shown a statistically significant improvement. 
Geographical differences have an impact on both parameters and the causes of 
regional differences should be investigated further to gather evidence on this 
neglected aspect of Fabry disease management. Further studies are required to 
confirm the results found herein and to monitor the status of diagnosis and treatment 
delays in Fabry disease. 
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Table 1 Delay in years between onset of symptoms and diagnosis and between diagnosis and onset of treatment of index patients, 1 
by year of diagnosis (n = 598 index patients with available diagnosis date and diagnosed during or after 2001; n = 467 of these 2 





(n = 26) 
Boys 
(n = 55) 
Total 
children 
(n = 81) 
Adult females 
(n = 256) 
Adult males 
(n = 261) 
Total adults 
(n = 517) 
Delay between symptom 
onset and diagnosis (years) 
2001–2006 n (missing) 5 (7) 16 (7) 21 (14) 64 (43) 67 (21) 131 (64) 
  Mean (SD) 4.0 (4.3) 6.0 (5.2) 5.5 (5.0) 16.4 (16.5) 17.0 (13.8) 16.7 (15.1) 
  Median (95% CI) 3.0 (0.0–9.0) 5.0 (1.0–11.0) 5.0 (1.0–9.0) 12.0 (7.0–19.0) 19.0 (9.0–22.0) 14.0 (9.0–20.0) 
 2007–2013 n (missing) 3 (11) 20 (12) 23 (23) 82 (67) 112 (61) 194 (128) 
  Mean (SD) 1.3 (2.3) 4.9 (4.1) 4.4 (4.1) 15.1 (15.4) 14.7 (14.9) 14.9 (15.1) 
  Median (95% CI) 0.0 (0.0–4.0) 4.0 (1.0–8.0) 4.0 (0.0–8.0) 11.0 (5.0–17.0) 9.5 (6.0–13.0) 10.5 (8.0–13.0) 
  Wilcoxon p-value NS NS NS NS NS NS 
   Girls 
 (n = 14) 
Boys 
 (n = 45) 
Total children 
(n = 59) 
Adult females 
(n = 184) 
Adult males 
(n = 224) 
Total adults 
(n = 408) 
Delay between diagnosis and 
treatment onset (years) 
2001–2006 n (missing) 8 (0) 18 (0) 26 (0) 72 (0) 81 (0) 153 (0) 
  Mean (SD) 4.5 (3.6) 4.4 (3.1) 4.4 (3.2) 3.3 (2.8) 3.1 (3.0) 3.2 (2.9) 
  Median (95% CI) 3.4 (0.8–9.5) 4.4 (1.0–7.0) 4.3 (2.0–7.0) 2.8 (1.3–3.7) 1.8 (0.9–3.4) 2.1 (1.3–3.2) 
 2007–2013 n (missing) 6 (0) 27 (0) 33 (0) 112 (0) 143 (0) 255 (0) 
  Mean (SD) 1.6 (1.1) 1.2 (0.7) 1.3 (0.8) 1.4 (1.1) 1.1 (0.9) 1.2 (1.0) 
  Median (95% CI) 1.3 (0.7–3.6) 1.0 (0.7-1.4) 1.0 (0.8–1.4) 1.0 (0.9–1.2) 0.8 (0.7–1.0) 0.9 (0.8–1.1) 
  Wilcoxon p-value NS 0.002 <0.001 <0.001 <0.001 <0.001 






 CI, confidence interval; SD, standard deviation. 4 
(Missing) indicates the number of patients missing the dates of symptom and treatment onset. 5 






Table 2 Delay in years between onset of symptoms and diagnosis and between diagnosis and onset of treatment of index patients, 
by region and year of diagnosis (of the n = 598 patients with an available diagnosis date during or after 2001, n = 267 were from 
Europe and n = 331 were from the ROW; n = 467 were treated with ERT and included in the analysis of delay between diagnosis 



























(n = 11) 
Boys 
(n = 32) 
Total 
children 





















4 (3) 8 (2) 12 (5)  39 (23) 38 (8) 74 (31) 1 (4) 8 (5) 9 (9) 25 (20) 32 (13) 57 (33) 

























































1 (7) 8 (5) 9 (12)  30 (30) 35 (29) 65 (59) 2 (4) 12 (7) 14 (11)  52 (37) 77 (32) 129 
(69) 





















































  Wilcoxon 
p-value 
NS NS NS NS NS 0.048 NS NS NS NS NS NS 


















(n = 24) 
Adult 
females 










(n = 7) 
Boys 
(n = 28) 
Total 
children 





















6 (0) 8 (0) 14 (0) 43 (0) 41 (0)  84 (0) 2 (0) 10 (0) 12 (0) 29 (0) 40 (0) 69 (21) 


























































1 (0) 9 (0) 10 (0) 41 (0) 48 (0) 89 (0) 5 (0) 18 (0) 23 (0) 71 (0) 95 (0) 166 
(32) 

















































  Wilcoxon 
p-value 
NS NS NS NS NS NS NS <0.001 <0.001 <0.001 <0.001 <0.001 
CI, confidence interval; NS, not significant; SD, standard deviation. 
(Missing) indicates the number of patients missing the dates of symptom and treatment onset. 
 






Table 3 FOS-MSSI at treatment onset of adult patients by year of diagnosis (n = 467 




Statistics Adult females 
(n = 184) 
Adult males 
(n = 224) 
Total adults 
(n = 408) 
FOS-MSSI* 2001–2006 n (missing) 67 (5) 78 (3) 145 (8) 
  Mean (SD) 14.1 (9.6) 18.4 (10.9)  16.4 (10.5) 






 2007–2013 n (missing) 111 (1) 134 (9) 245 (10) 
  Mean (SD) 12.1 (7.7)  16.1 (10.1) 14.3 (9.3) 






  Wilcoxon p-value NS NS NS 
CI, confidence interval; FOS-MSSI, FOS-Mainz Severity Score Index; NS, not 
significant; SD, standard deviation. 
*Total MSSI scores <20 indicate mild affliction; 20–40 moderate; >40 severe affliction 
[21]. 
†2001–2006, adult females versus males: p = 0.016. 
‡2007–2013, adult females versus males: p = 0.003. 





















Table 4 Type of specialist who suspected Fabry disease in the index patients (n = 
864 patients had an available diagnosis date, n = 496 before 2006 and n = 368 
during 2007–2013) 
Type of specialist 
FD first suspected 
by 
All patients 







Overall 270 202 472 
Nephrologist 59 (21.9) 26 (12.9) 85 (18.0) 
Cardiologist 32 (11.9) 43 (21.3) 75 (15.9) 
Ophthalmologist 44 (16.3) 19 (9.4) 63 (13.4) 
Geneticist 8 (3.0) 45 (22.3) 53 (11.2) 
Dermatologist 39 (14.4) 6 (3.0) 45 (9.5) 
Neurologist 20 (7.4) 15 (7.4) 35 (7.4) 
Other 22 (8.2) 9 (4.5) 31 (6.6) 
General practitioner 16 (5.9) 13 (6.4) 29 (6.1) 
Pediatrician 22 (8.2) 6 (3.0) 28 (5.9) 
Internist 5 (1.9) 16 (7.9) 21 (4.5) 
Rheumatologist 2 (0.7) 3 (1.5) 5 (1.1) 
Gastroenterologist 1 (0.4) 1 (0.5) 2 (0.4) 
FD, Fabry disease. 












Figure 1 Cohort flow diagram 
 
Figure 2 Delay between symptom onset and diagnosis in index patients (n = 598 
index patients with available diagnosis date and diagnosed after 2001; n = 230 

































Registered in FOS at time of data 
extraction, N=1802
Date of Fabry disease diagnosis 
available, n=864 (91.4%)
Diagnosed between 2001 
and 2013, n=598 (69.2%)
Diagnosed between 2001 and 
2006, n=230 (26.6%)
Diagnosed between 2007 
and 2013, n=368 (42.6%)




Fulfilled definition of “index” 
patient, n=945 (52.4%)
Diagnosed before 2001, 
n=266
Did not fulfill definition of 
“index” patient, n=857 (47.6%)




















Table S1 Age at diagnosis, symptom onset, and ERT initiation overall and by year of diagnosis (n = 598 index patients with 
available diagnosis date and diagnosed during or after 2001) 
 
Characteristic Diagnosis period Statistics 
Girls (n = 
26) 




(n = 81) 
Adult females 
(n = 256) 
Adult males 
(n = 261) 
Total adults 
(n = 517) 
Age at diagnosis (years) Overall n (missing) 26 (0) 55 (0) 81 (0) 256 (0) 261 (0) 517 (0) 
  Mean (SD) 13.1 (3.6) 12.7 (3.3) 12.8 (3.4) 45.3 (13.2) 44.6 (14.7) 44.9 (14.0) 














 2001–2006 n (missing) 12 (0) 23 (0) 35 (0) 107 (0) 88 (0) 195 (0) 
  Mean (SD) 11.8 (4.2) 13.0 (2.7) 12.6 (3.3) 44.4 (12.3) 40.3 (14.9) 42.54 (13.7) 














 2007–2013 n (missing) 14 (0) 32 (0) 46 (0) 149 (0) 173 (0) 322 (0) 
  Mean (SD) 14.1 (2.7) 12.4 (3.7) 12.9 (3.5) 45.9 (13.8) 46.7 (14.2) 46.4 (14.0) 














  Wilcoxon p-
value 
NS NS NS NS <0.001 0.003 
Age at symptom onset 
(years) 
Overall n (missing) 8 (18) 36 (19) 44 (37) 146 (110) 179 (82) 325 (192) 
  Mean (SD) 10.6 (3.9) 7.9 (3.7) 8.43 (3.8) 29.8 (17.5) 28.7 (19.6) 29.2 (18.7) 






Characteristic Diagnosis period Statistics 
Girls (n = 
26) 




(n = 81) 
Adult females 
(n = 256) 
Adult males 
(n = 261) 
Total adults 
(n = 517) 














 2001–2006 n (missing) 5 (7) 16 (7) 21 (14) 64 (43) 67 (21) 131 (64) 
  Mean (SD) 10.2 (4.9) 7.1 (3.5) 7.9 (4.0) 27.3 (17.1) 24.3 (19.7) 25.8 (18.5) 














 2007–2013 n (missing) 3 (11) 20 (12) 23 (23) 82 (67) 112 (61) 194 (128) 
  Mean (SD) 11.3 (1.5) 8.6 (3.8) 9.0 (3.7) 31.8 (17.7) 31.3 (19.2) 31.5 (18.5) 














  Wilcoxon p-
value 
NS NS NS NS 0.013 0.004 
Age at ERT initiation 
(years) 
Overall n (missing) 14 (12) 45 (10) 59 (22) 184 (72) 224 (37) 408 (109) 
  Mean (SD) 16.7 (4.1) 15.5 (3.8) 15.8 (3.8) 49.4 (12.7) 45.8 (14.6) 47.4 (13.9) 














 2001–2006 n (missing) 8 (4) 18 (5) 26 (9) 72 (35) 81 (7) 153 (42) 
  Mean (SD) 17.7 (4.5) 17.5 (3.8) 17.6 (4.0) 49.5 (11.8) 43.2 (14.9) 46.2 (13.8) 














 2007–2013 n (missing) 6 (8) 27 (5) 33 (13) 112 (37) 143 (30) 255 (67) 
  Mean (SD) 15.3 (3.2) 14.1 (2.8) 14.31 (2.88) 49.31 (13.29) 47.25 
(14.28) 
48.2 (13.9) 






Characteristic Diagnosis period Statistics 
Girls (n = 
26) 




(n = 81) 
Adult females 
(n = 256) 
Adult males 
(n = 261) 
Total adults 
(n = 517) 














 Wilcoxon comparison p-value NS 0.005 0.003 NS 0.048 NS 
 
CI, confidence interval; ERT, enzyme replacement therapy; SD, standard deviation. 
(Missing) indicates the number of patients missing age at diagnosis, symptom onset and ERT initiation  
 
 
 
 
 
 
